Xiaoting Yang

Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides

Significance Alzheimers disease and several related disorders are associated with the assembly of specific proteins into ordered fibrillar aggregates. In Alzheimers disease, the key component of pathological aggregates, the Aβ peptide, is produced from a precursor protein in variable lengths: Aβ40 is more abundant and Aβ42 more aggregation-prone. To shed light on the molecular basis of disease progression, the aggregation process has been studied in vitro. New theoretical models allow us to relate kinetic measurements to the rates of the individual processes underlying the aggregation reaction. We find that the loss of two residues in Aβ40 relative to Aβ42 significantly slows nucleation of aggregates in solution, thereby shifting the mechanism yet more strongly towards nucleation on the surface of fibrils. The two major forms of the amyloid-beta (Aβ) peptide found in plaques in patients suffering from Alzheimer’s disease, Aβ40 and Aβ42, only differ by two amino acids in the C-terminal region, yet they display markedly different aggregation behavior. The origins of these differences have remained challenging to connect to specific molecular-level processes underlying the aggregation reaction. In this paper we use a general strategy to apply the conventional workflow of chemical kinetics to the aggregation of the Aβ40 peptide to identify the differences between Aβ40 and Aβ42 in terms of the microscopic determinants of the aggregation reaction. Our results reveal that the major source of aggregates in the case of Aβ40 is a fibril-catalyzed nucleation process, the multistep nature of which is evident through its saturation behavior. Moreover, our results show that the significant differences in the observed behavior of the two proteins originate not simply from a uniform increase in all microscopic rates for Aβ42 compared with Aβ40, but rather are due to a shift of more than one order of magnitude in the relative importance of primary nucleation versus fibril-catalyzed secondary nucleation processes. This analysis sheds light on the microscopic determinants of the aggregation behavior of the principal forms of Aβ and outlines a general approach toward achieving an understanding at the molecular level of the aberrant deposition of insoluble peptides in neurodegenerative disorders.

A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers.

Alzheimers disease is an increasingly prevalent neurodegenerative disorder whose pathogenesis has been associated with aggregation of the amyloid-β peptide (Aβ42). Recent studies have revealed that once Aβ42 fibrils are generated, their surfaces effectively catalyze the formation of neurotoxic oligomers. Here we show that a molecular chaperone, a human Brichos domain, can specifically inhibit this catalytic cycle and limit human Aβ42 toxicity. We demonstrate in vitro that Brichos achieves this inhibition by binding to the surfaces of fibrils, thereby redirecting the aggregation reaction to a pathway that involves minimal formation of toxic oligomeric intermediates. We verify that this mechanism occurs in living mouse brain tissue by cytotoxicity and electrophysiology experiments. These results reveal that molecular chaperones can help maintain protein homeostasis by selectively suppressing critical microscopic steps within the complex reaction pathways responsible for the toxic effects of protein misfolding and aggregation.

Quantitative analysis of intrinsic and extrinsic factors in the aggregation mechanism of Alzheimer-associated Aβ-peptide.

Disease related mutations and environmental factors are key determinants of the aggregation mechanism of the amyloid-β peptide implicated in Alzheimers disease. Here we present an approach to investigate these factors through acquisition of highly reproducible data and global kinetic analysis to determine the mechanistic influence of intrinsic and extrinsic factors on the Aβ aggregation network. This allows us to translate the shift in macroscopic aggregation behaviour into effects on the individual underlying microscopic steps. We apply this work-flow to the disease-associated Aβ42-A2V variant, and to a variation in pH as examples of an intrinsic and an extrinsic perturbation. In both cases, our data reveal a shift towards a mechanism in which a larger fraction of the reactive flux goes via a pathway that generates potentially toxic oligomeric species in a fibril-catalyzed reaction. This is in agreement with the finding that Aβ42-A2V leads to early-onset Alzheimer’s disease and enhances neurotoxicity.

Modulation of electrostatic interactions to reveal a reaction network unifying the aggregation behaviour of the Aβ42 peptide and its variants

The amyloid

On the role of sidechain size and charge in the aggregation of Aβ42 with familial mutations

\beta

Secondary nucleation in amyloid formation

peptide (A

Conserved S/T-residues of the human chaperone DNAJB6 are required for effective inhibition of Aβ42 amyloid fibril formation

\beta

The A beta 40 and A beta 42 peptides self-assemble into separate homomolecular fibrils in binary mixtures but cross-react during primary nucleation

42), whose aggregation is associated with Alzheimers disease, is an amphiphatic peptide with a high propensity to self-assemble. A

On-chip label-free protein analysis with downstream electrodes for direct removal of electrolysis products

\beta

A general reaction network unifies the aggregation behaviour of the A

42 has a net negative charge at physiological pH and modulations of intermolecular electrostatic interactions can significantly alter its aggregation behaviour. Variations in sequence and solution conditions lead to varied macroscopic behaviour, often resulting in a number of different mechanistic explanations for the aggregation of these closely related systems. Here we alter the electrostatic interactions governing the fibril aggregation kinetics by varying the ionic strength over an order of magnitude, which allows us to sample the space of different reaction mechanisms, and develop a minimal reaction network that explains the experimental kinetics under all the different conditions. We find that an increase in the ionic strength leads to an increased rate of surface catalysed nucleation over fragmentation and eventually to a saturation of this nucleation process. More generally, this reaction network connects previously separate systems, such as mutants of A